Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Taking Action to Individualize Ovarian Cancer Care: Somatic Vs Germline Testing

August 24th 2022

In this third episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, explain the differences between germline and somatic testing in patients with ovarian cancer.

FDA Grants Breakthrough Therapy Designation to Taletrectinib for ROS1+ NSCLC

August 23rd 2022

The FDA has granted a breakthrough therapy designation to taletrectinib for use as a potential therapeutic option in adult patients with advanced or metastatic ROS1-positive non–small cell lung cancer who were ROS1 inhibitor naïve or who previously received crizotinib.

CCNE1 Amplifications Tied to Racial Disparities in Serous Endometrial Cancer Outcomes

August 18th 2022

Julian Schink, MD, discusses a study evaluating racial differences in the mutational landscape of serous endometrial cancer, underscores the need for appropriate genomic testing and treatment for Black women with the disease, and explains the importance of racial representation across clinical trials.

Tumor Agnostic Role of TMB Biomarker Faces Challenges

August 18th 2022

Although tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic decision-making faces many challenges, and we are only beginning to fully understand its strengths and limitations.

Taking Action to Individualize Ovarian Cancer Care: Counseling Those with BRCA Mutations

August 17th 2022

In this second episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss how to counsel patients with ovarian cancer whose tumors harbor BRCA mutations.

Liquid Biopsy Assay Expands Offerings to Include MRD, Disease Recurrence Detection in Early-Stage Breast and Lung Cancer

August 16th 2022

The Guardant Reveal assay has been expanded for the detection of minimal residual disease and disease recurrence in patients with early-stage breast cancer and lung cancer.

FDA Green Lights NGS-Based Companion Diagnostic for Trastuzumab Deruxtecan in HER2-Mutated NSCLC

August 16th 2022

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic to identify patients with NSCLC harboring an activating HER2 mutation who may derive clinical benefit from treatment with fam-trastuzumab deruxtecan-nxki.

Tumor Agnostic Approval Targets BRAF V600E–Mutant Disease

August 15th 2022

Vivek Subbiah, MD, discusses the significance of the approval of dabrafenib plus trametinib for adult and pediatric patients 6 years or older with unresectable or metastatic BRAF V600E–mutant solid tumors and highlights future directions for tumor agnostic drug development.

FDA Approves VENTANA MMR RxDx To Identify dMMR Solid Tumors and as Companion Diagnostic for pMMR Endometrial Cancer

August 11th 2022

The FDA has expanded its approval of the VENTANA MMR RxDx panel to identify patients with mismatch repair–deficient solid tumors and as a companion diagnostic assay to determine eligibility for pembrolizumab as a treatment for patients with mismatch repair–proficient endometrial cancer.

Taking Action to Individualize Ovarian Cancer Care: Effect of BRCA on Treatment

August 10th 2022

In this first episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss how BRCA mutational status affects treatment decisions for patients with ovarian cancer.

Biomarker Testing Provides a Way Forward for Increasingly Accurate Lung Cancer Diagnosis and Management

August 4th 2022

Giuseppe Lo Russo, MD, PhD, highlights the future role of liquid biopsy, the evolution of targeted therapies for KRAS G12C mutations, data to look forward to with EGFR-targeted agents, and the striking effects the COVID-19 pandemic has had on the mortality rates of patients with lung cancer.

PC14586 Shows Preliminary Activity, Safety in p53 Y220C–Mutant Solid Tumors

July 28th 2022

The first-in-class p53 reactivator, PC14586, induced a response in approximately 1 of 4 patients with advanced solid tumors harboring p53 Y220C mutations and showcased an acceptable safety profile consisting primarily of grade 1 and 2 events.

Direct Partnership With Patients May Accelerate Cancer Research and Precision Oncology

July 27th 2022

During the past several decades, cancer research has produced revolutionary discoveries leading to dramatic results for many patients.

LAG-3 Fills a Complex Role in the Immune System

July 27th 2022

The LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.

Dr. Subbiah on the FDA Approval of Dabrafenib/Trametinib in BRAF V600E–Mutated Solid Tumors

July 27th 2022

Vivek Subbiah, MD, discusses the FDA approval of dabrafenib plus trametinib for the treatment of patients with BRAF V600E–mutated unresectable or metastatic solid tumors.

Dr. Adashek on Targeting Molecular Alterations to Treat Multiple Tumor Types

July 22nd 2022

Jacob J. Adashek, DO, discusses how targeting molecular alterations is key for treating multiple types of cancer.

FDA Approves Crizotinib for ALK+ Inflammatory Myofibroblastic Tumors

July 14th 2022

The FDA has approved crizotinib for adult and pediatric patients aged 1 year and older with unresectable, recurrent, or refractory inflammatory ALK-positive myofibroblastic tumors.

FDA Grants Orphan Drug Designation to PBI-200 for NTRK Fusion–Positive Solid Tumors

July 7th 2022

The FDA has granted an orphan drug designation to PBI-200 for the treatment of patients with NTRK fusion–positive solid tumors, including primary and metastatic brain tumors.

Real-World Data Underscore Importance of NTRK Gene Fusions in Tumor Agnostic Therapies

July 6th 2022

The role of NTRK gene fusions across multiple cancer types have led investigators to confirm the marker in real-world data analyses.

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

June 29th 2022

A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.